OLOPATADINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
| Metabolism | Olopatadine is predominantly metabolized in the liver via glucuronidation and to a lesser extent via cytochrome P450 (CYP450) isoenzymes, primarily CYP3A4. |
| Excretion | Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites) |
| Half-life | Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours) |
| Protein binding | ~55% bound primarily to albumin |
| Volume of Distribution | 0.5–1.0 L/kg; moderate distribution in total body water |
| Bioavailability | Ophthalmic: minimal systemic absorption (<2%); intranasal: ~30% systemic bioavailability |
| Onset of Action | Ophthalmic: 30–60 minutes; intranasal: ~15 minutes |
| Duration of Action | Ophthalmic: 8–12 hours; intranasal: 12–24 hours; clinical effect persists for 8–12 hours after single dose |
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl < 30 mL/min) due to limited data; no specific dose adjustment recommended. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Use with caution in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Children ≥2 years: Same as adult dosing (one drop of 0.1% ophthalmic solution twice daily or 0.2% once daily). For children <2 years, safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment required. Use same dosing as adults. Monitor for ocular adverse effects due to possible age-related reduced tear production and ocular surface changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions For ophthalmic use only may cause mild transient burning or stinging.
| Breastfeeding | Olopatadine is excreted in rat milk. It is not known whether it is excreted in human milk. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need. M/P ratio not available. |
| Teratogenic Risk | Olopatadine hydrochloride is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenic effects at doses up to 600 mg/kg/day (rat) and 400 mg/kg/day (rabbit). There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. |
■ FDA Black Box Warning
None
| Common Effects | Eye pain Eye irritation Abnormal eye sensation Eye discomfort Sleepiness Weakness Dryness in mouth |
| Serious Effects |
["Hypersensitivity to olopatadine or any component of the formulation."]
| Precautions | ["Not for injection or oral use.","Avoid contamination of the container tip.","May cause transient burning or stinging upon instillation.","Use with caution in patients with known hypersensitivity to any component of the formulation.","Pregnancy and lactation: use only if clearly needed."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for maternal adverse effects such as somnolence or headache. |
| Fertility Effects | No significant effects on fertility observed in animal studies. In rats, there was no impairment of fertility at oral doses up to 200 mg/kg/day. |